capryloyl salicylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: capryloyl salicylic acid
• 英文别名: n-Octanoyl salicylate；octanoyl 2-hydroxybenzoate
• 化学式: C₁₅H₂₀O₄
• 分子量: 264.321
• InChiKey: KONVNJDNYREFLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  19
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  capryloyl salicylic acid 在 三溴化硼 、 sodium carbonate 、 水杨酸 、 potassium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

  摘要：

  该发明涉及公式I和公式II的化合物或其药用可接受盐，以及其多晶形、溶剂合物、对映体、立体异构体和水合物。含有公式I或公式II化合物的有效量的药物组合物；以及治疗或预防炎症性肠病的方法可制备为口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠内、糖浆或注射。这些组合物可用于治疗胃肠疾病和炎症，如炎症性肠病、溃疡性结肠炎、轻度至中度克罗恩病、类风湿关节炎、炎症性关节炎、银屑病性关节炎、肝硬化和特发性荨麻疹。

  公开号：

  US20160120839A1
• 作为产物：
  描述：

  水杨酸 在 氯化亚砜 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.5h， 生成 capryloyl salicylic acid
  参考文献：
  名称：

  炎症性腸疾患の治療のための組成物及び方法

  摘要：

  This invention relates to compounds of Formula I and Formula II or their pharmaceutically acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers, and hydrates thereof. Pharmaceutical compositions comprising an effective amount of a compound of Formula I or Formula II. Methods for treating or preventing inflammatory bowel diseases can be formulated for oral, oral cavity, rectal, topical, transdermal, transmucosal, intravenous, non-oral administration, syrup formulations, or injections. Such compositions can be used for the treatment of inflammatory bowel diseases, ulcerative colitis, mild to moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, cirrhosis, and idiopathic urticaria gastrointestinal diseases.【Selection figure】None

  公开号：

  JP2015522549A

文献信息

• Compositions and methods for the treatment of inflammatory bowel disease
  申请人：Kandula Mahesh

  公开号：US09498461B2

  公开（公告）日：2016-11-22

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.

  该发明涉及式I和式II化合物或其药用可接受的盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包括有效量的式I或式II化合物的药物组合物；以及用于治疗或预防炎症性肠病的方法可以制成口服、颊下、直肠、局部、经皮、经粘膜、静脉、肠内、糖浆或注射剂。这些组合物可用于治疗胃肠疾病和炎症，如炎症性肠病、溃疡性结肠炎、轻至中度的克罗恩病、类风湿关节炎、炎性关节炎、银屑病性关节炎、肝硬化和特发性荨麻疹。
• 炎症性腸疾患の治療のための組成物及び方法
  申请人：セリックスビオ プライヴェート リミテッド

  公开号：JP2015522549A

  公开（公告）日：2015-08-06

  本発明は、定式Ｉおよび定式ＩＩまたはその薬学的に許容される塩の化合物、ならびに多形体、溶媒和物、鏡像異性体、立体異性体および水和物に関する。定式Ｉまたは定式ＩＩの化合物の有効量を含む医薬組成物。および炎症性腸疾患を治療または予防するための方法は、経口、口腔、直腸、局所、経皮、経粘膜、静脈内、非経口投与、シロップ剤、または注射用に製剤化することができる。このような組成物は、炎症性腸疾患、潰瘍性大腸炎、軽度から中等度のクローン病、関節リウマチ、炎症性関節炎、乾癬性関節炎、肝硬変および特発性蕁麻疹胃腸疾患の治療及び炎症に使用することができる。【選択図】なし

  This invention relates to compounds of Formula I and Formula II or their pharmaceutically acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers, and hydrates thereof. Pharmaceutical compositions comprising an effective amount of a compound of Formula I or Formula II. Methods for treating or preventing inflammatory bowel diseases can be formulated for oral, oral cavity, rectal, topical, transdermal, transmucosal, intravenous, non-oral administration, syrup formulations, or injections. Such compositions can be used for the treatment of inflammatory bowel diseases, ulcerative colitis, mild to moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, cirrhosis, and idiopathic urticaria gastrointestinal diseases.【Selection figure】None
• Cosmetic compositions comprising Manilkara multinervis and extracts thereof
  申请人：Cognis IP Management GmbH

  公开号：EP2289485A1

  公开（公告）日：2011-03-02

  The present invention is directed to the use of Manilkara multinervis, preferably the use of an extract of Manilkara multinervis, for the preparation of or in a cosmetic composition.

  本发明的目的是将多刺马尼拉（Manilkara multinervis），最好是将多刺马尼拉（Manilkara multinervis）提取物用于制备化妆品组合物或在化妆品组合物中使用。
• Skin care composition
  申请人：The Procter & Gamble Company

  公开号：US10265262B2

  公开（公告）日：2019-04-23

  A thickened aqueous composition containing about 0.01% to about 10%, by weight, of an superabsorbent polymer, about 0.1% to about 20%, of a silicone elastomer; about 0.1% to about 20%, by weight, of a fatty alcohol; and from about 20% to about 98% of water.

  一种增稠的水性组合物，含有约 0.01%至约 10%（按重量计）的超吸水性聚合物、约 0.1%至约 20%的硅酮弹性体、约 0.1%至约 20%（按重量计）的脂肪醇以及约 20%至约 98%的水。
• Superabsorbent polymers and starch powders for use in skin care compositions
  申请人：The Procter & Gamble Company

  公开号：US10285926B2

  公开（公告）日：2019-05-14

  A skin care composition is provided that has an oil phase mixture and a water phase. The oil phase mixture has from about 5% to about 30% by weight of the composition, of a wax material and optionally from about 1% to about 20% by weight of the composition, of an oil that is liquid at room temperature. The oil phase mixture has a melting point of about 25° C. to about 50° C. The water phase has from about 0.1% to about 5%, by weight of the composition, of a superabsorbent polymer and from about 20% to about 85% by weight of the composition of water. The composition also has from about 6% to about 30%, by weight of the composition, of particulate material selected from the group consisting of starch particles, silicone elastomer particles and combinations thereof.

  一种护肤组合物具有油相混合物和水相。按组合物重量计，油相混合物中蜡材料的含量约为 5%至 30%，而按组合物重量计，油在室温下呈液态，可选含量约为 1%至 20%。油相混合物的熔点约为 25 摄氏度至 50 摄氏度。水相中有约 0.1%至约 5%（按组合物重量计）的超吸水性聚合物和约 20%至约 85%（按组合物重量计）的水。按组合物重量计，该组合物还含有约 6%至约 30%的微粒材料，这些微粒材料选自淀粉微粒、硅酮弹性体微粒及其组合。